cGvHD
Chronic GVHD risk score (CIBMTR)       Prognosis of chronic graft versus host disease  
Value Points
Risk factor 0 points 1 point 2 points
Age (years)
Age (years) ≤ 29 30 - 59 ≥ 60
Prior acute GVHD (yes/no)
Prior acute GVHD No Yes -
Time from transplant to cGVHD (months)
Time from transplant to cGVHD (months) ≥ 5 < 5 -
Bilirubin at onset of cGVHD (umol/L)
Bilirubin at onset of cGVHD (umol/L) ≤ 34 - > 34
Bilirubin at onset of cGVHD (mg/dL)
[mg/dL] [≤ 2]
[> 2]
Karnofsky performance status at cGVHD onset (%)
    Karnofsky performance status at cGVHD onset ≥ 80% < 80% -
Platelet count at cGVHD onset (x109/L)
Platelet count at cGVHD onset (x109/L) ≥ 100 < 100 -
Donor type
    Donor type HLA identical sibling, well-matched or partially-matched unrelated Other related or mismatched unrelated [1]  [1] Well-matched = no defined mismatches and no untested loci; partially-matched = one defined mismatch or untested locus; mismatched = ≥2 known mismatched or untested  -
Disease status at transplantation
    Disease status at transplantation [2] [2] Early disease = allograft in CR1 (acute leukemia) or first chronic phase (CML) or MDS categories RA or RARS; Intermediate disease = CR2 or later (ALL) or second chronic  Early Intermediate Advanced
Sex mismatch (donor/­recipient)
    Sex mismatch (donor/­recipient) Male/­Male, Female/­Female, Male/­Female Female/­Male -
GVHD prophylaxis
    GVHD prophylaxis Ciclosporin +/- methotrexate +/- other Tacrolimus +/- methotrexate +/- other, OR T-cell depletion -
Score Risk group 5-year overall survival (%) 5-year non-relapse mortality (%)
0 - 2 1
Sum of score1 - bilirubin (umol/L)       3 - 6 2
Sum of score2 - bilirubin (mg/L)       7 - 8 3
Risk group       9 - 10 4
5-year overall survival (%)       11 5
5-year non-relapse mortality (%)       ≥ 12 6